Light-chain (AL) amyloidosis · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Dexamethasone (Vd) Variant #01 | — | R 8 080 | 28d | ~9.4 mo | ~38.7 mo | ~11 | ~R 88 876 PFS proxy · indirect | 10 |
Bortezomib and Melphalan Variant #01 | — | R 3 617 | — | — | — | — | — | — |
Melphalan monotherapy Variant #01 | — | R 71 | 42d | — | 22.2 mo | — | — | 1 |
3 of 3 regimens shown